Evaluation of efficacy and safety of apatinib treatment in advanced gastric cancer

Autor: Fanfan Li, Nianfei Wang, Zhendong Chen, Xiuwei Wu, Mingjun Zhang, Yang Yang, Tong Sun
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
medicine.medical_specialty
Abdominal pain
Pyridines
Nausea
Antineoplastic Agents
lcsh:RC254-282
Gastroenterology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Quality of life
Stomach Neoplasms
Internal medicine
Biomarkers
Tumor
Humans
Medicine
Radiology
Nuclear Medicine and imaging
Apatinib
Protein Kinase Inhibitors
Aged
Aged
80 and over
business.industry
gastric cancer
Therapeutic effect
vascular endothelial growth factor receptor-2
Common Terminology Criteria for Adverse Events
General Medicine
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Survival Analysis
humanities
Treatment Outcome
030104 developmental biology
quality of life
Oncology
chemistry
Response Evaluation Criteria in Solid Tumors
030220 oncology & carcinogenesis
Vomiting
Female
medicine.symptom
Tomography
X-Ray Computed
business
Zdroj: Journal of Cancer Research and Therapeutics, Vol 15, Iss 2, Pp 365-369 (2019)
ISSN: 0973-1482
Popis: Aim: We aimed to evaluate the efficacy and safety of apatinib treatment and its impact on the quality of life (QOL) of patients with advanced gastric cancer (GC) who experienced failure with at least two chemotherapeutic regimens. Materials and Methods: All patients received apatinib at a daily dose of 500 mg for 4 weeks per cycle until it was stopped due to disease progression, intolerable toxicity. Response Evaluation Criteria in Solid Tumors version 1.1 and Common Terminology Criteria for Adverse events 4.0 were used to assess tumor responses and toxicities, respectively. The European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-STO22 were used to assess the impact on patient's QOL. Results: Twenty-five patients were enrolled, but only 24 were evaluated for therapeutic effects. After apatinib treatment, none of the patients achieved complete response (CR), one achieved partial response (PR), and eight had stable disease (SD), resulting in a disease control rate of 37.5% (CR + PR + SD). Responses to questions regarding abdominal pain, nausea/vomiting, insomnia, constipation, and diarrhea in QLQ-C30 and abdominal pain and reflux in QLQ-STO22 were changed over the course of treatment (P < 0.05). The QOL score was elevated after three treatment cycles, but it was not considered statistically significant (P > 0.05). Conclusion: Results indicated that apatinib was effective in heavily pretreated patients with advanced GC who experienced failure with two or more line chemotherapies. The toxicities were tolerable or could be clinically controlled. Apatinib treatment alleviated some of the clinical symptoms but did not improve QOL significantly.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje